$MEIP
MEI Pharma, Inc.

2014 Q4 Form 10-Q Financial Statement

#000119312514399669 Filed on November 06, 2014

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2013 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.420M $2.440M $1.810M
YoY Change 24.1% 34.81% 98.9%
% of Gross Profit
Research & Development $6.703M $6.566M $3.102M
YoY Change 52.34% 111.67% 99.87%
% of Gross Profit
Depreciation & Amortization $10.00K $16.00K $13.00K
YoY Change 0.0% 23.08% 62.5%
% of Gross Profit
Operating Expenses $9.118M $9.005M $4.913M
YoY Change 43.61% 83.29% 99.23%
Operating Profit -$9.118M -$9.005M -$4.913M
YoY Change 43.61% 83.29% 99.23%
Interest Expense $10.00K $10.00K $20.00K
YoY Change -66.67% -50.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$9.110M -$8.990M -$4.900M
YoY Change 44.15% 83.47% 99.19%
Income Tax $1.000K $0.00 $1.000K
% Of Pretax Income
Net Earnings -$9.109M -$8.993M -$4.896M
YoY Change 44.04% 83.68% 98.7%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$386.3K -$415.2K -$286.2K
COMMON SHARES
Basic Shares Outstanding 21.61M shares 21.61M shares 17.12M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q4 2014 Q3 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $78.70M $42.10M $31.50M
YoY Change 31.61% 33.65% 751.35%
Cash & Equivalents $23.66M $17.04M $31.50M
Short-Term Investments $55.10M $25.00M
Other Short-Term Assets $500.0K $400.0K $600.0K
YoY Change -44.44% -33.33% 500.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $79.24M $42.42M $32.11M
YoY Change 30.64% 32.11% 736.97%
LONG-TERM ASSETS
Property, Plant & Equipment $79.00K $75.00K $50.00K
YoY Change 71.74% 50.0% 117.39%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $497.0K $502.0K $511.0K
YoY Change -0.4% -1.76% -1.54%
TOTAL ASSETS
Total Short-Term Assets $79.24M $42.42M $32.11M
Total Long-Term Assets $497.0K $502.0K $511.0K
Total Assets $79.74M $42.92M $32.62M
YoY Change 30.39% 31.58% 648.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.152M $1.111M $557.0K
YoY Change 166.01% 99.46% 4.5%
Accrued Expenses $4.730M $4.197M $908.0K
YoY Change 192.16% 362.22% -17.23%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.882M $5.308M $1.465M
YoY Change 183.44% 262.32% -10.12%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $6.882M $5.308M $1.465M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $6.900M $5.300M $1.500M
YoY Change 187.5% 253.33% -6.25%
SHAREHOLDERS EQUITY
Retained Earnings -$141.5M -$132.4M -$101.2M
YoY Change 31.65% 30.88% 15.55%
Common Stock $0.00 $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $72.86M $37.61M $31.15M
YoY Change
Total Liabilities & Shareholders Equity $79.74M $42.92M $32.62M
YoY Change 30.39% 31.58% 648.96%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2013 Q3
OPERATING ACTIVITIES
Net Income -$9.109M -$8.993M -$4.896M
YoY Change 44.04% 83.68% 98.7%
Depreciation, Depletion And Amortization $10.00K $16.00K $13.00K
YoY Change 0.0% 23.08% 62.5%
Cash From Operating Activities -$6.450M -$6.730M -$4.063M
YoY Change 44.3% 65.64% 63.37%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K $6.000K
YoY Change 200.0%
Acquisitions
YoY Change
Other Investing Activities -$30.04M $10.00M
YoY Change 50.2%
Cash From Investing Activities -$30.05M $10.00M -$6.000K
YoY Change 50.25% -166766.67% 200.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 43.10M 0.000
YoY Change 31.68%
NET CHANGE
Cash From Operating Activities -6.450M -6.730M -4.063M
Cash From Investing Activities -30.05M 10.00M -6.000K
Cash From Financing Activities 43.10M 0.000
Net Change In Cash 6.600M 3.270M -4.069M
YoY Change -20.1% -180.36% 63.48%
FREE CASH FLOW
Cash From Operating Activities -$6.450M -$6.730M -$4.063M
Capital Expenditures -$10.00K $6.000K
Free Cash Flow -$6.440M -$4.069M
YoY Change 44.07% 63.48%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q2 meip Public Float Maximum Value
PublicFloatMaximumValue
75000000
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21607296 shares
CY2012Q3 meip Milestone Payments Maximum Amount
MilestonePaymentsMaximumAmount
75200000
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31504000
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21607296 shares
CY2014Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
465121 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.65
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1678095 shares
CY2014Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.46
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
113000000 shares
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2014Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21607296 shares
CY2014Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5308000
CY2014Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2014Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
170047000
CY2014Q3 us-gaap Assets
Assets
42917000
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17041000
CY2014Q3 us-gaap Short Term Investments
ShortTermInvestments
25021000
CY2014Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
427000
CY2014Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
75000
CY2014Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1111000
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
37609000
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-132438000
CY2014Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2014Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4197000
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
0
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42917000
CY2014Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
4700000
CY2014Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
236969
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
609210
CY2014Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
353000
CY2014Q3 us-gaap Assets Current
AssetsCurrent
42415000
CY2014Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
42062000
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35573000
CY2014Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21607296 shares
CY2014Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.11
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1194854 shares
CY2014Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2014Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
113000000 shares
CY2014Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2014Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2014Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21607296 shares
CY2014Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4616000
CY2014Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
168637000
CY2014Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1708000
CY2014Q2 us-gaap Stockholders Equity
StockholdersEquity
45192000
CY2014Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-123445000
CY2014Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2014Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2908000
CY2014Q2 us-gaap Common Stock Value
CommonStockValue
0
CY2014Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
49808000
CY2014Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
83000
CY2014Q2 us-gaap Assets
Assets
49808000
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13777000
CY2014Q2 us-gaap Short Term Investments
ShortTermInvestments
35016000
CY2014Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
435000
CY2014Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
48793000
CY2014Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
497000
CY2014Q2 us-gaap Assets Current
AssetsCurrent
49290000
CY2012Q3 us-gaap Stock Issued During Period Shares Purchase Of Assets
StockIssuedDuringPeriodSharesPurchaseOfAssets
195756 shares
CY2012Q3 us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
500000
CY2012Q3 meip Upfront And Milestone Payments
UpfrontAndMilestonePayments
200000
CY2012Q3 meip Agreement Termination Notice Period
AgreementTerminationNoticePeriod
P90D
CY2012Q3 meip Percentage Of Purchases From Major Suppliers
PercentageOfPurchasesFromMajorSuppliers
1.00 pure
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.014 pure
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.576 pure
CY2013Q3 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4063000
CY2013Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0 shares
CY2013Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17116611 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.68
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2013Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6421590 shares
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2013Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000
CY2013Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
18000
CY2013Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
146000
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4913000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-4896000
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1811000
CY2013Q3 us-gaap Share Based Compensation
ShareBasedCompensation
1176000
CY2013Q3 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-4069000
CY2013Q3 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-6000
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
4913000
CY2013Q3 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
20000
CY2013Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2013Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-230000
CY2013Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
13000
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3102000
CY2014Q3 dei Trading Symbol
TradingSymbol
MEIP
CY2014Q3 dei Entity Registrant Name
EntityRegistrantName
MEI Pharma, Inc.
CY2014Q3 dei Amendment Flag
AmendmentFlag
false
CY2014Q3 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2014Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2014Q3 dei Document Type
DocumentType
10-Q
CY2014Q3 dei Document Period End Date
DocumentPeriodEndDate
2014-09-30
CY2014Q3 dei Entity Central Index Key
EntityCentralIndexKey
0001262104
CY2014Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2014Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2014Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y9M18D
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.017 pure
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.170 pure
CY2014Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.52
CY2014Q3 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6731000
CY2014Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0 shares
CY2014Q3 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P14Y
CY2014Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21652223 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.15
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2014Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6845761 shares
CY2014Q3 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. The Company uses estimates for certain accruals, including drug development costs, clinical and pre-clinical study fees and expenses, and share-based compensation, among others. Actual results could differ from those estimates.</p> </div>
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.42
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
483241 shares
CY2014Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M18D
CY2014Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P2Y9M18D
CY2014Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
12000
CY2014Q3 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
4998000
CY2014Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-144000
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9005000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-8993000
CY2014Q3 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2439000
CY2014Q3 us-gaap Share Based Compensation
ShareBasedCompensation
1410000
CY2014Q3 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3264000
CY2014Q3 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
9995000
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
9005000
CY2014Q3 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-597000
CY2014Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1289000
CY2014Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
16000
CY2014Q3 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
14993000
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6566000
CY2014Q3 meip Lease Expiration Month And Year
LeaseExpirationMonthAndYear
2015-06
CY2014Q3 meip Lease Arrangement Rent Area
LeaseArrangementRentArea
8800 sqft
CY2014Q3 meip Percentage Of Likelihood Of Income Tax Being Sustained
PercentageOfLikelihoodOfIncomeTaxBeingSustained
0.50 pure
CY2014Q3 meip Cash And Cash Equivalent Maturity Period Maximum
CashAndCashEquivalentMaturityPeriodMaximum
P3M

Files In Submission

Name View Source Status
0001193125-14-399669-index-headers.html Edgar Link pending
0001193125-14-399669-index.html Edgar Link pending
0001193125-14-399669.txt Edgar Link pending
0001193125-14-399669-xbrl.zip Edgar Link pending
d792804d10q.htm Edgar Link pending
d792804dex311.htm Edgar Link pending
d792804dex312.htm Edgar Link pending
d792804dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
meip-20140930.xml Edgar Link completed
meip-20140930.xsd Edgar Link pending
meip-20140930_cal.xml Edgar Link unprocessable
meip-20140930_def.xml Edgar Link unprocessable
meip-20140930_lab.xml Edgar Link unprocessable
meip-20140930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending